SCHEMBL22925752

SCHEMBL22925752

O=C(NO)c1ccc(Nc2ncc(-c3ccc(Cl)cc3)o2)cn1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VCP P55072 6/20 0.63
SIRT7 Q9NRC8 1/20 0.52
DGAT1 O75907 1/20 0.46
FLT1 P17948 3/20 0.45
KDR P35968 3/20 0.45
FLT4 P35916 2/20 0.45
PIK3CG P48736 1/20 0.44
HDAC1 Q13547 5/20 0.44
HDAC6 Q9UBN7 4/20 0.44
HDAC3 O15379 2/20 0.44
HDAC2 Q92769 2/20 0.44
ALOX5 P09917 1/20 0.44
HDAC8 Q9BY41 2/20 0.43
HDAC4 P56524 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC10 Q969S8 1/20 0.43
HDAC11 Q96DB2 1/20 0.43
HDAC9 Q9UKV0 1/20 0.43
HDAC5 Q9UQL6 1/20 0.43
P4HTM Q9NXG6 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28733778 0.89 VCP (0.64) VCPSIRT7DGAT1FLT1KDR
SCHEMBL31013371 0.86 VCP (0.46) VCPDGAT1FLT1KDRFLT4
SCHEMBL22925735 0.86 VCP (0.46) VCPDGAT1FLT1KDRFLT4
SCHEMBL28733638 0.86 VCP (0.60) VCPSIRT7DGAT1FLT1KDR
SCHEMBL22925699 0.81 VCP (0.60) VCPSIRT7DGAT1FLT1KDR
SCHEMBL29620974 0.81 VCP (0.51) VCPSIRT7DGAT1FLT1KDR
SCHEMBL28733865 0.81 VCP (0.60) VCPSIRT7DGAT1FLT1KDR
SCHEMBL29696320 0.81 VCP (0.60) VCPSIRT7DGAT1FLT1KDR
SCHEMBL29620886 0.80 VCP (0.54) VCPSIRT7DGAT1FLT1KDR
SCHEMBL28733624 0.80 VCP (0.54) VCPSIRT7DGAT1FLT1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220274970-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2022-09-01 US disclosed
WO-2021012018-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2021-01-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220274970-A1 INHIBITOR COMPOUNDS SERPINB1, MMP1, SSB VCP 595/4885SIRT7 964/4885DGAT1 164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.